+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides

Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides

Australian and New Zealand Journal of Medicine 1: Suppl 2:47-56

(PDF 0-2 workdays service: $29.90)

Accession: 042565124

Download citation: RISBibTeXText

PMID: 5005131

Related references

Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete & Metabolisme 17(1 Pt 2): 224-231, 1991

Biguanides in oral antidiabetic therapy: indications and limitations. Medicina 8(3): 262-268, 1988

Mode of action of oral hypoglycaemic agents. II. Sulphonylureas & biguanides in rats. Indian Journal of Biochemistry 6(1): 36-39, 1969

Long term observations with oral hypoglycemic drugs: sulphonylureas, biguanides and their combination. Indian Journal of Medical Sciences 24(7): 393-403, 1970

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Current Medical Research and Opinion 25(3): 607-615, 2010

The oral antidiabetic agents. The mode of action of sulphonylureas. Anglo-German Medical Review. Deutsch-Englische Medizinische Rundschau 1: 310-333, 1962

Clinical experiences with oral antidiabetic HB 419 (glibenclamide). Arzneimittel-Forschung 19(8): Suppl:1439-45, 1969

Clinical experiences with administration of oral antidiabetic agent Buformin. Casopis Lekaru Ceskych 110(18): 420-421, 1971

Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Medicine 2(2): E26-E38, 2008

On The Clinical Adjustability Of Various Forms Of Diabetes In Delayed-Action Insulin Therapy, Combined And Exclusively Oral Therapy With Sulfonylurea Derivatives And Biguanides. Munchener Medizinische Wochenschrift 107: 83-88, 1965

Oral antidiabetic monotherapy and combination treatment with glybenclamide (HB 419) and biguanides of insulin receiving diabetics of the adult type. Medizinische Klinik 65(3): 109-112, 1970

Sulphonylureas and biguanides do not affect insulin binding in H35 hepatoma cells. Diabetes Research 3(6): 307-310, 1986

New oral antidiabetic agents and current strategies of peroral antidiabetic therapy (PAD). Vnitrni Lekarstvi 48(6): 517-522, 2002

Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetologica 45(1): 53-59, 2008